Cellectis (NASDAQ:CLLS) Coverage Initiated at StockNews.com

StockNews.com assumed coverage on shares of Cellectis (NASDAQ:CLLS - Free Report) in a research report sent to investors on Sunday. The brokerage issued a sell rating on the biotechnology company's stock.

Cellectis Price Performance

Shares of Cellectis stock traded down $0.01 during trading on Friday, hitting $1.90. 43,300 shares of the company's stock traded hands, compared to its average volume of 45,910. The company has a market cap of $105.61 million, a PE ratio of -1.47 and a beta of 3.09. The firm's fifty day moving average price is $2.17 and its 200 day moving average price is $2.35. Cellectis has a twelve month low of $0.96 and a twelve month high of $3.77. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.92 and a quick ratio of 1.92.

Cellectis (NASDAQ:CLLS - Get Free Report) last released its quarterly earnings data on Tuesday, August 6th. The biotechnology company reported ($0.28) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.33) by $0.05. Cellectis had a negative return on equity of 78.90% and a negative net margin of 401.83%. The firm had revenue of $9.50 million during the quarter, compared to analyst estimates of $6.00 million. Analysts forecast that Cellectis will post -0.54 earnings per share for the current year.

Hedge Funds Weigh In On Cellectis

Several large investors have recently made changes to their positions in CLLS. Principal Financial Group Inc. boosted its position in shares of Cellectis by 6.2% during the first quarter. Principal Financial Group Inc. now owns 424,533 shares of the biotechnology company's stock worth $1,125,000 after purchasing an additional 24,906 shares in the last quarter. Baillie Gifford & Co. lifted its holdings in Cellectis by 1.3% during the first quarter. Baillie Gifford & Co. now owns 827,248 shares of the biotechnology company's stock worth $2,192,000 after acquiring an additional 10,605 shares in the last quarter. XTX Topco Ltd acquired a new position in Cellectis in the second quarter valued at about $29,000. Long Focus Capital Management LLC grew its stake in Cellectis by 2.9% in the second quarter. Long Focus Capital Management LLC now owns 4,617,293 shares of the biotechnology company's stock valued at $8,634,000 after acquiring an additional 130,000 shares during the period. Finally, First Affirmative Financial Network bought a new stake in shares of Cellectis in the third quarter worth about $45,000. Institutional investors and hedge funds own 63.90% of the company's stock.

About Cellectis

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.